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G protein-coupled receptors (GPCRs) represent the largest class of cell surface proteins and thus constitute
an important family of therapeutic targets. Therefore, significant effort has been put towards the
identification of novel ligands that can modulate the activity of a GPCR target with high efficacy and
selectivity. However, due to limitations inherent to the most common techniques for GPCR ligand
discovery, there is a pressing need for more efficient and effective ligand screening methods especially
for the identification of potential allosteric modulators. Here we present a high-throughput, label-free
and unbiased screening approach for the identification of small molecule ligands towards GPCR targets
based on affinity mass spectrometry. This new approach features the usage of target-expressing cell
membranes rather than purified proteins for ligand screening and allows the detection of both
orthosteric and allosteric ligands targeting specific GPCRs. Screening a small compound library with this
approach led to the rapid discovery of an antagonist for the 5-HT receptor and four positive allosteric
modulators for GLP-1 receptor that were not previously reported.Introduction
The superfamily of G-protein-coupled receptors (GPCRs) is the
largest class of cell surface receptors and they play a central role
in a variety of pathophysiological conditions.1 GPCRs are
recognized as an important family of therapeutic targets upon
which an estimated 30–40% of marketed drugs act.2 While
much effort has gone into identifying novel ligands that can
modulate the activity of a GPCR target with high efficacy and
selectivity, conventional techniques for GPCR drug discovery
remain subject to several critical limitations. For example,ity, 201210, Shanghai, China. E-mail:
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tion (ESI) available. See DOI:
is work.receptor functional assays, which measure GPCR downstream
signaling effectors,3 are inadequate for identifying allosteric or
biased signaling modulators and oen generate hits unsuitable
for subsequent optimization.4 Radioligand binding assays,
which assess receptor–ligand interactions on cell surfaces, are
increasingly restricted due to high production costs and
hazards to human health.3 Alternative receptor binding assays
using uorescently labeled probes require careful compound
design and optimization because of the impact of uorophore
attachment on ligand affinity and efficacy.5,6 Finally, while
surface plasma resonance and NMR have recently been
employed in the identication of GPCR ligands,7–9 they require
highly puried and stabilized receptors, which are not feasible
for a number of targets and their current throughput is not
amenable to large-scale compound library screening.
Affinity mass spectrometry (MS) has emerged as a powerful
approach for analyzing protein–ligand interaction and it plays
a vital role in early-phase drug discovery.10–12 In a typical affinity
MS-based workow, the ligand–bound protein complexes are
rst separated from unbound compounds by ultraltration or
size exclusion chromatography. Then the ligands dissociated
from the complexes are identied by LC-MS/MS analysis.10,11,13,14
Similar to other biophysical approaches, affinity MS has been
widely applied to ligand identication for puried protein
targets from compound libraries.This journal is © The Royal Society of Chemistry 2018
Fig. 1 GPCR ligand identification through affinity MS screening. (a)
Experimental workflow. (b) BI derived from LC-MS measurement
reflects the relative binding affinity of each compound to the target. (c)
Representative LC-MS chromatograms of cocktail mix-1 (reference),
compounds from the target incubation (target) and from control
incubation (control). (d) Multivariate analysis of the LC-MS data with an
OPLS-DA model.17












































View Article OnlineAffinity MS-based assays have been developed for screening
chemical ligands towards different soluble protein targets,
especially enzymes and kinases of therapeutic values.10,12,13,15–17
However, the application of affinity MS techniques to ligand
discovery for membrane receptors is substantially hampered
due to the difficulty of obtaining membrane proteins of suffi-
cient purity, activity and stability. Whitehurst et al. rst show-
cased the adaptation of affinity MS to screening ligands towards
the membrane receptor CXCR4 that belongs to the GPCR
family.18 To search for an optimal form of the receptor for
screening purposes, the authors laboriously compared different
epitope tags and detergents to nd the best conditions for
expression and purication of the receptor. They argued that
sufficient yield and purity of the receptor is essential for
successful usage of this screening approach.18 However, it is
widely recognized that many transmembrane receptors are
unstable when isolated away from the cell membrane. Thus,
biophysical techniques that can only analyze puried proteins
such as isothermal titration calorimetry (ITC), surface plasmon
resonance (SPR) as well as affinity MS approach are not
amenable to many receptors that are attractive drug targets.
Here we developed a novel affinity MS technique that enables
ligand screening towards wild-type active receptors embedded in
the cell membranes. Most signicantly, the challenging and
laborious receptor purication step is eliminated in our work-
ow. We implemented this new approach to achieve high-
throughput, label-free and unbiased ligand screening towards
two GPCR targets, which resulted in the discovery of unreported
orthosteric ligands and allostericmodulators for specic GPCRs.
Results and discussion
We rst applied our methodology using the human 5-hydroxy-
tryptamine 2C receptor (5-HT2CR), an anti-psychotic drug target
for treating depression, schizophrenia and other mental disor-
ders.19,20 Themembrane fractions from insect cells expressing 5-
HT2CR were directly incubated with a cocktail of compounds
while the protein concentration was kept in large excess over
any compound (see ESI†). Cell membranes were separated from
the compound solution by ltration. Compounds associated
with the receptor-expressing membranes were released aer
washing and subjected to liquid chromatography coupled to
high-resolution mass spectrometry (LC-MS) analysis (Fig. 1a).
Insect cell membranes expressing rhodopsin were prepared in
the same manner and used as a negative control (Fig. S1†). To
assess the specic association of a given compound with the
receptor, we calculated a binding index (BI) dened as the ratio
of MS response of the compound detected in the target versus
the control incubations (Fig. 1b). This BI parameter allowed us
to compare the affinities of different compounds bound to the
GPCR target and discern compounds non-specically interact-
ing with the cell membranes.
To validate our method, we incubated the 5-HT2CR-
expressing membranes with a mixture of 5 known ligands to
the receptor and 45 unrelated compounds. Given all positive
ligands with Ki 0.3–29 nM showing BI > 2 (Fig. S2†) as well as our
previous experience in selecting ligands to soluble proteinThis journal is © The Royal Society of Chemistry 2018targets with affinity mass spectrometry,15–17 we dened a BI
threshold of 2 for distinguishing putative ligands to the
receptor from non-binders. Next, we employed the affinity MS
assay to screen a collection of 4333 small molecules against 5-
HT2CR. This library was divided into 9 cocktails (each contain-
ing 480 or 493 compounds) and each was separately incubated
with the target-expressing and control membranes in quadru-
plicate. Representative LC-MS chromatograms are shown in
Fig. 1c. Multivariate analysis17 of the LC-MS data from reference,
target and control revealed that the composition of compounds
associated with 5-HT2CR was substantially deviated from that in
the mix-1 reference and the control (Fig. 1d).
Using stringent data processing criteria for compound
annotation and hit selection (see ESI†), we identied a total of
23 initial hits from screening the 9 cocktails (Fig. 2, full data set
in Table S1†). Twelve were well characterized antagonists for 5-
HT2CR or a closely-related subfamily member 5-HT2AR with
a mean BI of 2.16 to 9.71 (full data set in Table S2†). Most of
these known ligands showed <10 nM binding affinity to the
receptor as determined by the radioligand competition assay.
Results from a thermal shi assay using puried 5-HT2CR
indicated that 11 known ligands could signicantly enhance the
receptor's thermostability thereby validating their direct inter-
actions with the receptor. Notably, 98 compounds in our
collection that were reported to be 5-HT2CR ligands had BI < 2
from the primary screening. While their IC50 or Ki values from
the ChEMBL database were all above 10 nM, 85% had IC50 or Ki
> 100 nM towards 5-HT2CR. Therefore, the stringent BI cut-off
dened for hit selection ensured identication of highest
affinity ligands with a minimal false-positive rate.Chem. Sci., 2018, 9, 3192–3199 | 3193
Fig. 2 Affinity MS screening of a 4333-member compound library split
into 9 cocktails against 5-HT2CR. Initial hits (mean BI > 2 and p < 0.05)
are indicated by red dots while grey dots represent negatives.
Fig. 3 (a) Hit validation with the affinity MS assay on amixture of the 11
putative ligands. Confirmed ligands (mean BI > 2 and p < 0.01) are
designated by asterisks, with data shown as mean and s.d. of four
individual assays. (b) Affinity of 3943 to 5HT2CR determined by radio-
ligand binding assay. (c) Inhibition of 5HT2CR activation by 3943
revealed by calcium mobilization assay. MES, mesulergine. Ki and IC50
measurement in (b) and (c) were represented by mean and s.d. from
experimental triplicates. (d) Docked poses of 3943 (blue) in the 5-
HT2CRmodel (yellow). (e) Schematic of the interactions between 3943
and 5-HT2CR. Residue colors: negatively charged, red; hydrophobic/
aromatic, green; polar, cyan; glycine, gray. Interactions: hydrogen
bonds to the side chain, dashed magenta line; hydrogen bonds to the
main chain, solid magenta line; p–p interaction, dark green line.












































View Article OnlineTo verify the 11 initial hits with no documented binding to
the 5-HT2 receptor family, a simple mixture was created by
pooling and incubating them with the receptor-expressing
membranes. Four hits were veried in this secondary affinity
MS assay (Fig. 3a). Those that were invalidated could have
resulted from compound misidentication or altered binding
properties in the original complex mixtures. The unknown
ligand 3943 had a thermostabilizing effect on the puried
receptor (Table S3†) and it further exhibited moderate antago-
nist activity in the calciummobilization assay as it inhibited the
5-HT induced activation of 5-HT2CR with IC50 of 1.01 mM
(Fig. 3b). Notably, this compound displayed even stronger
antagonism against 5-HT2AR (IC50¼ 0.12 mM) and 5-HT2BR (IC50
¼ 0.51 mM) (Fig. S3a†). The radioligand competition assay
veried potent antagonist binding of 3943 to all three 5-HT2
receptor subtypes in the nanomolar range, with stronger affinity
to 5-HT2A/2BR than 5-HT2CR (Fig. 3c, S3b†). It was not surprising
to identify a new antagonist against three 5-HT2 receptor
subfamily members using our approach because of the high
sequence homology and very similar ligand binding pockets
among them. A molecular docking study demonstrated key
interactions between the cyproheptadine scaffold in 3943 and
conserved residues in the transmembrane helices III, V, VI and
VII of 5-HT2A/2B/2C receptors (Fig. 3d and e).
Next we applied our affinity MS assay to a more challenging
target, the human glucagon-like peptide-1 receptor (GLP-1R).
GLP-1R is a class B GPCR that mediates the action of peptide
hormone GLP-1 and exerts important functions in glucose
homeostasis.21,22 Although small molecule modulators of GLP-
1R are expected to serve as critical chemical tools for investi-
gating ligand-directed biased signaling, very few non-peptidic
GLP-1R agonists have been published.21 Before embarking on
a real library screening, we rst optimized our approach using
two negative allosteric modulators (NAMs) of the receptor,
PF06372222 and NNC0640. Both NAMs were readily identied3194 | Chem. Sci., 2018, 9, 3192–3199from a 50-compound mixture with the mean BI of 16.66 for
PF06372222 and 3.31 for NNC0640, indicating their signicant
association with the receptor in the membrane fraction
(Fig. S4†).
We then employed the affinity MS approach to screen the
previous nine compound cocktails using insect cell membranes
expressing the GLP-1R transmembrane domain (TMD). A total
of 29 putative ligands were obtained from the primary screening
(Fig. 4, full date set in Table S4†), and none of them have been
previously linked with GLP-1R.
In the secondary affinity MS screening assay, 18 were
conrmed to bind the receptor (Fig. 5a). Importantly, in this
step we also prepared cell membranes expressing another GLP-
1R TMD construct with stabilizing mutations commonly
exploited in the GPCR crystallography.23,24 Interestingly, all
ligands identied in our primary screening abrogated their
binding to the thermostabilized receptor (Fig. 5a). This result
highlighted the unique advantage of using cell membranes
expressing wild-type receptors in ligand screening given that
puried receptors with mutations could be locked in an inactiveThis journal is © The Royal Society of Chemistry 2018
Fig. 4 Affinity MS screens of the 9 cocktails from the above
compound library against GLP-1R. Initial hits (mean BI > 2 and p < 0.05)
are indicated by red dots with grey dots representing negatives.
Fig. 5 (a) Affinity MS assay on amixture of 29 initial hits usingwild-type
(WT) receptor-expressing membranes or point-mutated receptor-
expressing membranes. Confirmed ligands (mean BI > 2 and p < 0.01)
are designated by asterisks with data shown as mean and s.d. of four
individual assays. (b) Affinity of each test ligand to GLP-1R determined
by radioactive GLP-1 binding assay. (c) EnhancedGLP-1R cell activity in
the presence of GLP-1 (0.02 nM) by each test ligand. pEC50
measurement for (b) and (c) is provided in Table S5.† (d) Docked pose
for 3286 (orange) in the GLP-1 (green)/GLP-1R (light blue) complex
model. (e) Schematic representation of interactions between 3286 and
GLP-1R. Residues of GLP-1 are underlined. Color codes for residues
and interactions are as in Fig. 3e. While the predicted binding site is
formed by extracellular loop 2 (ECL2), extracellular loop 3 (ECL3),
transmembrane helix VI and GPL-1, 3268 seems to strengthen the
interactions between ECL2, ECL3 and GLP-1, which may explain its
PAM activity in the presence of GLP-1.












































View Article Onlineconformation and fail to engage ligands that only interact with
the active receptor. Subsequent radioligand binding assay
revealed that four ligands (901, 3286, 4170, and 4279)
augmented peptide binding to the receptor with EC50 in the low
micromolar range (Fig. 5b, Table S5†). When conducting
another binding assay using radiolabeled exendin-4(9-39), which
is a GLP-1R antagonist targeting the extracellular domain
(ECD), we observed no obvious alteration of the binding potency
between exendin-4(9-39) and GLP-1R by any of the four ligands
(Fig. S5a†). Moreover, increasing the amount of NAM
PF06372222 in the presence of the four ligands did not compete
off any ligand in the affinity MS assay (Fig. S5b†).
These results collectively imply that the four novel ligands
allosterically modulate the binding of GLP-1 to the orthosteric
pocket of GLP-1R and that their targeting sites are likely to be
different from the NAM binding pocket.25 Concordantly, all four
ligands substantially promoted intracellular cAMP accumula-
tion in the presence of GLP-1 with EC50 in the low micromolar
range (Fig. 5c, Table S5†). By contrast, none of them stimulated
cAMP production in cells expressing glucagon receptor (GCGR),
a close homolog of GLP-1R, demonstrating the high selectivity
of the four ligands for GLP-1R (Fig. S5c†). Therefore, we
conclude that the four ligands identied in this study are all
positive allosteric modulators (PAMs) of GLP-1R. For compound
3286, we performed molecular docking based on a previous
model of the GLP-1/GLP-1R complex26 to reveal a possible
binding mode of this PAM (Fig. 5d and e). While the precise
targeting sites and activation mechanism of the four PAMs
warrant further investigation, we are excited by the discovery of
a new class of ligands for this important therapeutic target and
the efficiency of our approach in identication of novel GPCR
ligands.
A notable limitation of our approach lies in the detectability
issue for certain compounds by our LC-MS analytical platform.
In our study, the percentage of detectable compounds in eachThis journal is © The Royal Society of Chemistry 2018library cocktail by electrospray MS in the positive mode varied
between 66–86% (Fig. S6†). Thus, the receptor binding capa-
bility of the undetectable compounds remains unclear. This
could be partially addressed using MS instruments of increased
sensitivity and operating in both positive and negative modes,
or by optimizing the LC system for effective separation of
abnormal compounds. Nevertheless, our current LC-MS
method is generally applicable to the analysis of most drug-
like small molecules.Conclusions
In summary, we developed an efficient and convenient affinity
MS approach for high-throughput identication of GPCR
ligands. Our new approach demonstrates ve major advantages
over the conventional receptor functional assays or ligand
binding assays: (1) both the receptor and compounds are label-
free; (2) the receptor target, with minimal sequence modica-
tion, is embedded in the cell membranes to retain its nativeChem. Sci., 2018, 9, 3192–3199 | 3195












































View Article Onlineconformation during ligand interaction; (3) measurement of
direct receptor–ligand binding in an unbiased manner facili-
tates identication of allosteric modulators targeting unchar-
acterized binding sites; (4) quantitative comparison of ligand
response with a GPCR control enables identication of specic
ligands with medium affinity while maintaining a low false-
positive rate; and (5) protein purication commonly required
in affinity-based ligand screens is unnecessary, thus reducing
experimental cost and eliminating purication-inherent draw-
backs. Our screening technology, benchmarked on two GPCR
targets, can be readily adapted to other membrane receptors. Its
integration with complementary biophysical and functional
assays could expedite the discovery of new GPCR modulators
with therapeutic potential. Apart from direct application to drug
discovery towards membrane receptors, our approach is ex-
pected to aid in delineating the membrane protein–small
molecule interaction network within the cell.Experimental
Preparation of cell membranes over-expressing 5HT2C-R or
GLP1-R TMD
The 5-HT2CR construct was produced comprising residues 40–
393 with residues from intracellular loop 3 (245–301) replaced
by thermo-stabilized E. coli apocytochrome b562RIL (BRIL). It
was expressed with an N-terminal FLAG tag and a C-terminal
10 His tag. The GLP-1R TMD construct comprised residues
128–431 with residues from intracellular loop 2 (258–263)
replaced by rubredoxin and it was expressed with an N-terminal
FLAG tag followed by BRIL and a C-terminal 10 His tag. The
rhodopsin construct comprised residues 2–331 with residues
from intracellular loop 3 (235–241) replaced by BRIL and it was
expressed with an N-terminal FLAG tag and a C-terminal 10
His tag. All three proteins were expressed using the Bac-to-Bac
Baculovirus Expression System (Invitrogen) in Spodoptera fru-
giperda (Sf9) cells. Cells were infected at a density of 2–3  106
cells per mL with baculovirus at a multiplicity of infection (MOI)
of 5. Cultures were grown at 27 C and harvested 48 h aer
infection. Cell pellets were lysed by repeated washing and ultra-
centrifugation in the hypotonic buffer of 10 mM HEPES (pH
7.5), 10 mM MgCl2, 20 mM KCl, and the high osmotic buffer of
10 mM HEPES (pH 7.5), 1.0 M NaCl, 10 mMMgCl2, 20 mM KCl,
both with EDTA-free protease inhibitor cocktail tablets (Roche).
The washed membranes were re-suspended in the hypotonic
buffer with 30% glycerol and stored at80 C for further usage.
Cell membrane proteins were extracted using 1% SDS in 0.1%
NaOH and total protein concentration was measured with the
BCA quantication kit (TIANGEN, China). The amount of 5-
HT2CR and GLP-1R present in the membrane extract was
determined using ELISA with anti-His antibody (Genscript,
China).Compound library preparation
The library of 4333 small molecule members was purchased
from Topscience (Shanghai, China) in DMSO stock. It was
divided into nine cocktails (mix-1 to mix-9) by pooling different3196 | Chem. Sci., 2018, 9, 3192–3199sub-fractions of the library. Eight cocktails (mix-1 to mix-8)
comprised 480 compounds and the last one (mix-9)
comprised 493 compounds. No compounds were overlapped
between different cocktails. All cocktails were stored at 20 C.GPCR ligand identication with affinity mass spectrometry
Sample preparation for screening and hit validation. In the
primary screening, the membrane fraction expressing the
receptor (5HT2CR or GLP-1R TMD) was incubated with
a compound cocktail in a buffer of 10 mM HEPES (pH 7.5),
10 mMMgCl2 and 20 mM KCl in a total volume of 200 mL for 1 h
at 25 C. During incubation, each compound concentration was
at 50 nM and the receptor concentration was estimated to be
200–250 nM. The membrane fraction was separated from the
incubation solution by rapid vacuum ltration through Multi-
ScreenHTS FB Filter Plate (Millipore) using a MultiScreenHTS
vacuum Manifold (Millipore). Aer washing the membrane
fraction six times with ice-cold 150 mM ammonium acetate (pH
7.5), methanol was added to the membranes (100 mL, 4 times)
and the ltrate, containing compounds initially associated with
the membranes, was collected. We then used the Ostro™ 96-
well plate (Waters) to deplete phospholipids co-eluted with the
compounds of interest. The eluted samples were evaporated by
a speed vacuum and reconstituted in 50% methanol before LC-
MS analysis. The control sample was prepared by using
rhodopsin-expressing membranes in incubation with the same
amount of total membrane proteins as the target-expressing
membranes. Each pair of target and control samples was
prepared in quadruplicate.
In secondary screening, initial hits were pooled to make
a simple mixture, which was incubated with target and control
membranes separately under the same conditions. In the
5HT2CR experiment, 11 unknown ligands were pooled whereas
in the GLP-1R experiment, all 29 initial hits were pooled.
Compound concentration in incubation was still 50 nM and the
receptor concentration was increased to 300 nM. In the method
validation study, both target-expressing and control
membranes were incubated with a 50-compound mixture con-
taining specic known ligands and unrelated compounds with
the same receptor and compound concentrations as mentioned
above. Each pair of target and control samples was prepared in
quadruplicate.
LC-MS analysis. Samples were analyzed on a Shimazu L30A
UPLC system (Shimazu) coupled to a TripleTOF 6600 mass
spectrometer (AB SCIEX) operating in the positive ion mode.
Chromatographic separation was performed on a ZORBAX
Eclipse Plus C18 column (3.5 mm, 2.1  100 mm, Agilent) at
a ow rate of 400 mL min1 and maintained at 40 C with the
mobile phases of water/0.1% formic acid (A) and acetonitrile/
0.1% formic acid (B). In the primary screening, the LC gradient
was as follows: 0–2 min, 5% B; 2–2.1 min, 5–20% B; 2.1–22 min,
20–35% B; 22–30 min, 35–60% B; 30–30.5 min, 60–90% B; 30.5–
35 min, 90% B; and re-equilibration for 5 min. In the secondary
screening, a shorter LC gradient was applied: 0–2 min, 5% B; 2–
2.1 min, 5–20% B; 2.1–10 min, 20–35% B; 10–13 min, 35–60% B;
13–13.5 min, 60–90% B; 13.5–16 min, 90% B; and re-This journal is © The Royal Society of Chemistry 2018












































View Article Onlineequilibration for 4 min. Full-scan mass spectra were acquired in
the range of 100–1500 m/z with major ESI source settings:
voltage 5.0–5.5 kV; gas temperature 500 C; curtain gas 35 psi;
nebulizer gas 55 psi; and heater gas 55 psi. MSMS spectra were
acquired on selected compound precursors with collision
energy set at 45 eV with a CE spread of 15 eV and other ion
source conditions identical to MS full scans. For each sample
set, we rst injected a reference sample (the compound mixture
alone) followed by four pairs of target and control samples.
LC-MS data processing and hit selection. First, compounds
in the reference were identied by extracting selected ion
chromatograms (EICs) using Peakview 2.2 (AB SCIEX) based on
accurate mass measurement (<10 ppm deviation) and isotope
envelop matching (<20% difference from the theoretical
envelop). H+ and Na+ adducts were considered for compound
detection. Then compounds in target and control samples were
identied by meeting the above criteria plus retention time (RT)
matching with corresponding peaks in the reference (<0.2 min
shi). Ambiguous peaks of isomeric compounds in the cocktail
were distinguished by acquiring MS/MS spectra or injecting
individual standards for RT differentiation. For each compound
condently identied in target and control samples, its BI was
calculated by dividing the EIC intensity of the compound
detected in the target sample by that in the control. Given that
target and negative control proteins were expressed at similar
levels and their concentrations during ligand incubation were
close to each other (<20% difference), we did not modify the BI
ratios with the protein concentration ratios. Initial hits were
selected based on a mean BI > 2 and p < 0.05 from four repli-
cates. Hits were validated in the second-round MS affinity assay
based on a mean BI > 2 and p < 0.01 from four replicates. P-
values were determined by a two-tailed t-test of BI values against
unity. Putative ligands were searched in ChEMBL, DrugBank,
Binding DB and SciFinder databases to nd out whether they
are known ligands to the receptor target.Purication of 5-HT2CR protein for the thermal shi assay
The receptor protein was extracted from the previously puried
membranes by adding n-dodecyl-D-maltopyranoside (DDM,
Affymetrix) and cholesteryl hemisuccinate (CHS, Sigma) to the
membrane suspension to a nal concentration of 1.0% (w/v)
and 0.2% (w/v), respectively, in buffer of 50 mM HEPES (pH
7.5) and 150 mM NaCl, while stirring continuously at 4 C for
2 h. The supernatant was isolated by centrifugation at 160 000g
for 30 min followed by overnight incubation in TALON IMAC
resin (Clontech) at 4 C. The resin was washed with ten column
volumes of wash buffer 1 (50 mMHEPES, pH 7.5, 800 mMNaCl,
0.1% (w/v) DDM, 0.02% (w/v) CHS, 20 mM imidazole, 10% (v/v)
glycerol) and followed by ve column volumes of wash buffer 2
(50 mMHEPES, pH 7.5, 150 mMNaCl, 0.05% (w/v) DDM, 0.01%
(w/v) CHS, 10% (v/v) glycerol). Proteins were eluted in 5 column
volumes of wash buffer 2 with 250 mM imidazole. Protein purity
and monodispersity were assessed by SDS-PAGE and analytical
size-exclusion chromatography.
The thermal shi assay using a CPM uorescent dye (Sigma)
was performed as described in the literature.27 Briey, puriedThis journal is © The Royal Society of Chemistry 2018receptor protein pre-mixed with the CPM dye was incubated
with a given compound at 200 mM at 4 C for 1 h. The protein
sample was heated step-wise on a Rotor-Gene Thermo-optical
Analyzer (QIAGEN Gmbh) from 25 C to 95 C. Upon tempera-
ture rise, the proteins unfolded and cysteine residues were
exposed to form adducts with CPM, which were detected by
uorescence at 387/463 nm using an EnVision multilabel plate
reader (PerkinElmer). From the normalized thermal stability
curve, melting temperatures (Tm) were obtained by tting the
curve with a Boltzmann sigmoidal function using GraphPad
Prism. Comparison of Tm for the apo receptor and receptor
incubated with a compound gave rise to Tm shi (DTm) for the
compound.
Calcium mobilization assay
HEK293T cells stably transfected with 5-HT2A/2B/2C receptor
were seeded in 384-well plates at a density of 15 000 cells per
well in DMEM containing 1% dialyzed FBS 8 h before assaying.
Aer removing the medium, cells were incubated (20 mL per
well) for 1 h at 37 C with Fluo-4 Direct dye (Invitrogen) and
reconstituted in a FLIPR buffer (1 HBSS, 2.5 mM probenecid,
and 20 mM HEPES, pH 7.4). Aer the dye loaded, cells were
placed in a FLIPR TETRA uorescence imaging plate reader
(Molecular Devices). Drug dilutions, prepared at 3 nal
concentration in FLIPR buffer and aliquoted into 384-well
plates, were also added to the FLIPR TETRA. The uidics
module and plate reader of the FLIPR TETRA were programmed
to read baseline uorescence for 10 s (1 read per s), then to add
10 mL of drug per well and to read for 6 min (1 read per s).
Fluorescence in each well was normalized to the average of the
rst 10 reads (i.e., baseline uorescence). Then the maximum-
fold increase, which occurred within 60 s aer drug addition
over baseline uorescence elicited by vehicle or a test
compound, was determined. In the test of potential positive
allosteric modulators and antagonists, 5-HT at EC20 (0.1 nM)
and at EC80 (3 nM) were added to the medium, respectively, for
receptor activation.
cAMP accumulation assay
The human GLP-1R and glucagon receptor (GCGR) cDNAs were
cloned into pcDNA3.1/V5-His-TOPO (Invitrogen). Aer 24 h
transfection, stably expressing CHO-K1 cells were selected on
750 mg mL1 G418 (Roche) for 2 weeks to obtain the clone with
the highest expression and potent cell activity. Stable cells were
seeded in 6-well plates for overnight culture before inoculation
into 384-well plates (8000 cells per well) for the assay. Accu-
mulation of cAMP was measured using the LANCE cAMP kit
(PerkinElmer) according to the manufacturer's instructions.
Briey, cells were incubated for 30 min in assay buffer (DMEM,
1 mM 3-isobutyl-1-methylxanthine) with varying concentrations
of each compound (2.3 nM to 50 mM) in the presence of GLP-1 or
glucagon (0.02 nM) at 37 C. Compound treatment was
quenched by adding lysis buffer containing LANCE reagents.
Plates were then incubated for 60 min at room temperature and
time-resolved FRET signals were measured at 620 nm and
650 nm by an EnVision multilabel plate reader (PerkinElmer).Chem. Sci., 2018, 9, 3192–3199 | 3197












































View Article OnlineRadioligand binding assays for different receptors
The 5-HT2A/2B/2CR binding assays were provided by the National
Institute of Mental Health Psychoactive Drug Screening
Program (NIMH PDSP), contract number HHSN-271-2008-
00025-C. Detailed procedures are available at https://
pdspdb.unc.edu/pdspWeb/. Briey, 5-HT2A/2B/2CR membrane
fractions were prepared from stable HEK293 cell lines or tran-
sient transfections. The radioligand used was 3H-ketanserin at
1–2 nM for 5-HT2AR;
3H-LSD at 1–2 nM for 5-HT2BR;
3H-
mesulergine at 1–3 nM for 5-HT2CR. Nonspecic binding was
determined in the presence of 10 mM clozapine for 5-HT2AR,
10 mM SB206553 for 5-HT2BR, and 10 mM ritanserin for 5-
HT2CR. Results were analyzed in GraphPad Prism with a built-in
competitive binding equation to obtain affinity values.
In the GLP-1R and GCGR binding assays, stable cell lines
were seeded onto 96-well poly-D-lysine treated cell culture plates
(PerkinElmer) at a density of 3  104 cells per well. Cells were
harvested aer 24 h post seeding, washed twice and incubated
with blocking buffer (F12 supplemented with 33 mM HEPES,
pH 7.4, and 0.1% bovine serum albumin (BSA)) for 2 h at 37 C.
They were then washed twice with PBS and incubated in
binding buffer (PBS supplemented with 10% BSA, pH 7.4) with
a test ligand at room temperature for 3 h. Cells were treated with
each ligand at varying concentrations (7.6 nM to 16.7 mM) in the
presence of 125I-GLP-1 (40 pM) or 125I-exendin-4(9-39) (40 pM).
Cells were then washed three times with ice-cold PBS and lysed
by 50 mL lysis buffer (PBS supplemented with 20 mM Tris–HCl,
1% Triton X-100, pH 7.4). The plates were subsequently counted
for radioactivity (counts per minute, CPM) in a scintillation
counter (MicroBeta2TM Plate Counter, PerkinElmer) using
a scintillation cocktail (OptiPhase SuperMix, PerkinElmer).
Molecular modeling and docking
Binding mode prediction was performed using graphical user
interface Maestro 10.4 in Schrödinger Suite 2015-4. For 5-
HT2CR, a homology model of the receptor was built based on the
crystal structure of 5-HT2BR28 (PDB: 4IB4) using the Advanced
Homology Modeling tool. For GLP-1R, a previously published
model26 was used and the allosteric binding site was identied
with the SiteMap tool. Ligand 3D structures were generated
using LigPrep 3.6. Molecular docking was carried out using
Induced Fit Docking with the extra precision docking score and
allowing optimization of residues within 5.0 Å.
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